Author:
Müller Marten,Merseburger Axel S.,Roesch Marie C.
Publisher
Springer Berlin Heidelberg
Reference24 articles.
1. AstraZeneca (2020) Lynparza approved in the EU for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-approved-in-the-eu-for-prostate-cancer.html. Zugegriffen: 31. Jan. 2023
2. Bertz J, Dahm S, Haberland J et al (2010) Verbreitung von Krebserkrankungen in Deutschland. Robert Koch-Institut. https://edoc.rki.de/bitstream/handle/176904/3226/23GSS31yB0GKUhU.pdf?sequence=1&isAllowed=y. Zugegriffen: 17. Febr. 2022
3. Cancer GBoD (2019) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol 5(12):1749–1768. https://doi.org/10.1001/jamaoncol.2019.2996
4. Catalona WJ (2018) Prostate cancer screening. Med Clin North Am 102(2):199–214. https://doi.org/10.1016/j.mcna.2017.11.001
5. Chadwick DJ, Kemple T, Astley JP et al (1991) Pilot study of screening for prostate cancer in general practice. Lancet 338(8767):613–616. https://doi.org/10.1016/0140-6736(91)90615-v